Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Towns wants answers on J&J's alleged "phantom recall"

This article was originally published in The Tan Sheet

Executive Summary

Rep. Edolphus Towns investigates whether Johnson & Johnson and subsidiary McNeil Consumer Healthcare hired contractors to buy all of a small Motrin stock-keeping unit as part of a "phantom recall" in 2008. "The company's motivation was apparently to save itself the embarrassment and potential financial loss associated with a recall," said Towns, chairman of the House Oversight and Government Reform Committee. The New York Democrat June 3 sent a 1letter to contractor WIS and a separate 2letter to Inmar Inc. - whose subsidiary Carolina Supply Chain Services may have recruited WIS to purchase the affected Motrin, Towns said. The letters ask the firms for details on what J&J contracted them to do. J&J OTC executive Colleen Goggins testified May 27 she was unaware of the contractors secretly purchasing the product, which failed to meet dissolution standards and was recalled formally in 2009 (3"The Tan Sheet" May 31, 2010)

You may also be interested in...



Congress Wants More Answers From J&J On "Phantom Recall"

Johnson & Johnson's response to a congressional inquiry regarding the alleged "phantom recall" of a Motrin product left a House committee chairman considering whether to subpoena additional information

J&J Faces Possible Criminal Liability As Post-Recall Overhaul Continues

FDA's drug center referred its review of Johnson & Johnson's manufacturing operations to the Office of Criminal Investigations, which will determine whether there is criminal liability in the quality control lapses that led to extensive recalls of OTC drugs

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel